B of A Securities Maintains Buy on Immunovant, Raises Price Target to $51
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry has maintained a Buy rating on Immunovant (NASDAQ:IMVT) and increased the price target from $49 to $51.
December 21, 2023 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities analyst Jason Gerberry maintains a Buy rating on Immunovant and raises the price target from $49 to $51.
The increase in price target by a reputable analyst typically signals a positive outlook on the stock, suggesting potential short-term price appreciation. As the rating is maintained at Buy and the target is raised, this indicates a stronger conviction in the company's future performance.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100